Market Context — Why This Technology, Why Now

The pharmaceutical industry is actively seeking next-generation drug targets beyond traditional receptor-ligand interactions, driven by the need for improved efficacy and reduced off-target effects. Rising R&D costs and extended development cycles necessitate platform technologies that can de-risk early-stage discovery and accelerate market entry. This patent offers a validated molecular mechanism to address these challenges, aligning with global trends towards precision medicine and advanced biological therapeutics.

Key Competitive Advantages
01

Utilizes M-LPH protein to provide a distinct cAMP/cGMP degradation pathway compared to existing PDE inhibitors, potentially reducing side effect risks and enhancing therapeutic efficacy.

02

Adjusting cAMP/cGMP levels allows for more selective targeting of disease-related pathways, potentially leading to drug discovery with high target specificity.

03

Patentability was established after comparison with four prior art documents, and the robust rights, having overcome two office actions, ensure stability for business development.

Market Opportunity
Drug Discovery and Pharmaceuticals
$45B–$50B globally (AI est.)
Drugs with novel mechanisms of action consistently command high demand, contributing to market expansion by addressing unmet medical needs.
Major pharmaceutical companies Biotech firms specializing in novel therapeutics Contract research organizations (CROs) for drug discovery
Diagnostics and Biomarkers
$10B–$15B globally (AI est.)
Fluctuations in cAMP/cGMP levels are recognized as biomarkers for various diseases, and this market is expanding with the advancement of precision medicine.
Diagnostic kit manufacturers Clinical laboratory service providers Medical device companies developing point-of-care diagnostics
Functional Foods and Supplements
$5B–$10B globally (AI est.)
As functional ingredients aimed at maintaining cellular homeostasis and improving metabolism, this market is growing with increasing health consciousness.
Nutraceutical companies Food and beverage manufacturers Health and wellness product developers
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent protects the core technology of an M-LPH protein-based cAMP/cGMP degrading agent through four claims. It was granted after overcoming two office actions and clearly differentiating from prior art, establishing a robust and highly stable patent right with low invalidation risk.

Competitive White Space

This patent primarily covers the M-LPH protein as a cAMP/cGMP degrading agent. White space exists in developing novel delivery systems for M-LPH, creating small molecule modulators of M-LPH activity, or exploring its role in non-degradation-related cellular processes.

Economic Impact
~$13.5M/year estimated R&D cost reduction per project (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Adopting this technology could reduce the verification period for cAMP/cGMP degradation mechanisms by an average of 1.5 years in the novel lead compound discovery and optimization process. A 20% reduction (1.5 years/10 years) in the average 10-year drug development cycle could equate to approximately $13.5M (AI est.) in annual R&D cost savings (based on $65M development cost × 20%), with additional benefits from accelerated market entry.

Speed to Market
5× faster than in-house development
The most time-consuming and costly early-stage R&D phases in drug discovery, specifically the identification of M-LPH protein and the establishment of its cAMP/cGMP degradation function, are already completed with this technology. Licensees can immediately leverage this foundational technology, potentially shortening time-to-market by approximately 4 years compared to in-house development from scratch. This could establish a competitive advantage for early product launch and revenue generation.
Competitive Positioning

X: Innovative Mechanism of Action
Y: Broad Market Impact

Business Models & Applications
💊 Pharmaceutical Development Licensing
License M-LPH for development as a novel therapeutic in specific disease areas. Licensees could significantly shorten R&D timelines by leveraging this pre-established foundational technology.
🔬 Research Reagent & Tool Provision
Offer M-LPH protein as a reagent or tool for studying cAMP/cGMP signaling pathways and analyzing cellular functions, targeting the basic research sector.
🧪 Diagnostic Co-Development
Leverage M-LPH's mechanism of action to co-develop biomarker detection kits for diagnosing or prognosing cAMP/cGMP-related diseases, potentially creating new diagnostic markets.
Adjacent Application Opportunities
🔬 Basic Research & Academia
Cellular Signaling Analysis Kit
Develop a cAMP/cGMP degradation kit utilizing M-LPH to streamline cellular signaling pathway research. This could significantly accelerate the elucidation of complex disease mechanisms and high-throughput screening for new drugs, impacting a ~$1.5B global research tools market (AI est.).
🧬 Gene & Cell Therapy
Cellular Function Modulation via Gene Introduction
Introducing the M-LPH gene into specific cells could modulate cAMP/cGMP levels in disease-relevant cells, potentially yielding therapeutic effects. This has promising applications in regenerative medicine and gene therapy, a market projected to reach ~$50B by 2030 (AI est.).
🍎 Functional Foods & Cosmetics
Cellular Metabolism Enhancing Supplements
Apply M-LPH's cellular function control to develop functional food and cosmetic ingredients that improve metabolism or offer anti-inflammatory effects. This could create new value in the wellness market, which is growing at ~5-10% annually.
Integration Roadmap — Estimated 21-Month Deployment
Phase 1: Technology Evaluation & Proof-of-Concept
Duration: 3 months
Conduct detailed analysis of the M-LPH mechanism of action, evaluate relevance to target diseases, and perform in vitro Proof-of-Concept to validate adoption benefits.
Phase 2: Lead Optimization & Preclinical Development
Duration: 12 months
Perform compound screening based on M-LPH, evaluate efficacy and safety in in vivo models, and conduct pharmacokinetic analysis to optimize preclinical candidates.
Phase 3: Clinical Development Preparation & Commercialization Plan
Duration: 6 months
Establish investigational drug manufacturing processes, engage with regulatory authorities, formulate clinical trial plans, and develop market entry strategies for commercialization.
Technical Feasibility
This technology is based on a specific molecular entity, the M-LPH protein, making it relatively easy to adopt for companies with existing biopharmaceutical manufacturing infrastructure or protein expression systems. Large-scale production of M-LPH using recombinant DNA technology and its integration into existing cell culture and purification processes are technically feasible, allowing for rapid technology transfer without significant capital investment.
Success Scenario
If adopted, this technology could enable licensees to efficiently create novel drug candidates that more precisely control intracellular cAMP/cGMP signaling. This could lead to the development of breakthrough drugs for diseases where conventional treatments have limited efficacy, establishing a competitive advantage in the market.
Patent Record
APPLICATION NO.
特願2020-077450
REGISTRATION NO.
7555094
FILING DATE
2020/04/24
GRANT DATE
2024/09/12
EXPIRATION DATE
2040/04/24
PATENT HOLDER
飯田　礼子
Examination History
2023年01月24日
出願審査請求書
2024年02月20日
拒絶理由通知書
2024年04月10日
手続補正書（自発・内容）
2024年04月10日
意見書
2024年05月14日
拒絶理由通知書
2024年07月05日
手続補正書（自発・内容）
2024年07月05日
意見書
2024年08月27日
特許査定